Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,697Revenue $M105Net Margin (%)-154.3Z-Score-0.8
Enterprise Value $M1,691EPS $-0.9Operating Margin %-152.0F-Score5
P/E(ttm))0Cash Flow Per Share $-0.8Pre-tax Margin (%)-153.7Higher ROA y-yY
Price/Book21.010-y EBITDA Growth Rate %0Quick Ratio4.3Cash flow > EarningsY
Price/Sales16.25-y EBITDA Growth Rate %0Current Ratio4.3Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-35.4Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)-132.1Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M188ROI % (ttm)-83.9Gross Margin Increase y-yY

Gurus Latest Trades with ARIA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARIAGeorge Soros 2014-12-31 Sold Out -0.01%$5.02 - $7.46
($6.28)
$ 9.7135%Sold Out0
ARIAGeorge Soros 2014-09-30 Reduce-0.04%$5.01 - $6.5
($5.84)
$ 9.7140%Reduce -85.00%150,000
ARIAGeorge Soros 2014-06-30 Add0.02%$6.3 - $8.52
($6.89)
$ 9.7129%Add 100.00%1,000,000
ARIAGeorge Soros 2014-03-31 Reduce-0.08%$6.46 - $8.99
($7.75)
$ 9.7120%Reduce -74.36%500,000
ARIAGeorge Soros 2013-12-31 Buy 0.11%$2.2 - $18.8
($5.16)
$ 9.7147%New holding1,950,000
ARIAGeorge Soros 2012-06-30 Sold Out -0.15%$14.6 - $17.82
($16.35)
$ 9.71-68%Sold Out0
ARIAGeorge Soros 2012-03-31 Buy 0.15%$12.73 - $16.32
($13.74)
$ 9.71-42%New holding635,000
ARIAGeorge Soros 2011-12-31 Sold Out -0.07%$8.03 - $12.5
($10.96)
$ 9.71-13%Sold Out0
ARIAGeorge Soros 2011-09-30 Buy 0.07%$7.63 - $13.34
($10.54)
$ 9.71-9%New holding496,847
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARIA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ARIA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FITZGERALD EDWARD MExecutive VP, CFO 2015-03-23Sell9,584$8.7211.35view
Cantor Maria ESVP, Corporate Affairs and HR 2015-03-23Sell16,954$8.869.59view
BERSTEIN DAVID LSVP, Chief IP Counsel 2015-03-23Sell4,375$8.7211.35view
Bollag Daniel MSr. VP, Reg. Affairs & Quality 2015-03-23Sell7,000$8.7211.35view
Duvall Martin JEVP, CCO 2015-03-23Sell4,834$8.810.34view
Haluska FrankSVP, Clinical R&D, CMO 2015-03-23Sell6,875$8.7111.48view
CLACKSON TIMOTHY PPresident, R&D, CSO 2015-03-23Sell32,741$8.889.35view
BERSTEIN DAVID LSVP, Chief IP Counsel 2015-03-23Sell4,375$8.7211.35view
Bollag Daniel MSr. VP, Reg. Affairs & Quality 2015-03-16Sell34,425$8.6212.65view
CLACKSON TIMOTHY PPresident, R&D, CSO 2015-02-20Sell49,035$821.38view

Press Releases about ARIA :

Quarterly/Annual Reports about ARIA:

News about ARIA:

Articles On GuruFocus.com
Sarah Ketterer of Causeway Capital's Answers to GuruFocus Q&A Apr 07 2014 
Weekly CEO Sells Highlight: U.S. Bancorp, Restoration Hardware Holdings Inc, Ariad Pharmaceuticals, Jul 20 2013 
Daniel Loeb's Top Three Increases of the First Quarter May 24 2013 
comment on ARIA Mar 15 2013 
comment on ARIA Mar 15 2013 
comment on ARIA May 16 2012 
Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
3 Biotech Stocks To Consider Buying Right Now Jan 10 2012 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
creiter note on ARIA Jan 03 2010 

More From Other Websites
ARIAD to Webcast Conference Call on First Quarter 2015 Financial Results Apr 23 2015
ARIAD to Webcast Conference Call on First Quarter 2015 Financial Results Apr 23 2015
7:35 am Ariad Pharm announces the issuance of its first U.S. patent on brigatinib, ARIAD's... Apr 22 2015
ARIAD Announces Issuance of Key U.S. Patent on Brigatinib Apr 22 2015
The BBJ's Five Things: Taxi win; Raytheon bets big; Ariad's defense; and why is Downtown Crossing so... Apr 22 2015
ARIAD Announces Results of Preclinical Studies on Brigatinib at the American Association for Cancer... Apr 21 2015
ARIAD Presents Updated Clinical Data on Brigatinib in Patients with ALK+ Non-Small Cell Lung Cancer Apr 17 2015
Biotech Stock Mailbag: Bluebird's Sickle Cell Data, Ariad's Faux Suitors, XBiotech Blech Apr 17 2015
Ariad Pharmaceuticals, Inc. (ARIA), Amgen, Inc. (AMGN): How Sarissa Capital’s Top Picks Beat the... Apr 15 2015
Five companies that may be looking to buy Ariad Pharmaceuticals Apr 14 2015
ARIAD Announces Approval of Iclusig (as Ponatinib Hydrochloride) in Canada Apr 06 2015
3 Risks Ariad Investors Ought to Know About Apr 03 2015
3 Things Ariad Has to Do to Be Profitable in 2018 Mar 27 2015
The young & the restless: 6 who are hot Mar 27 2015
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 25 2015
ARIAD Announces Dismissal of Shareholder Class Action Lawsuit in Federal District Court Mar 25 2015
ARIAD Announces Dismissal of Shareholder Class Action Lawsuit in Federal District Court Mar 25 2015
ARIAD and Medison Pharma Announce Approval of Iclusig (Ponatinib) in Israel Mar 24 2015
ARIAD Announces Presentations of Preclinical Data at American Association for Cancer Research Annual... Mar 19 2015
​MIT says cancer drug costs have outpaced quality increases Mar 18 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK